# A Phase 2 clinical trial has begun enrolling patients in the United States for an experimental immunotherapy.

*biotech · news · 2026-05-03 · Artvoice*

## Key points

- The Phase 1 SYNC-T trial in Mexico reported an 87% tumor response rate in metastatic prostate cancer.
- SYNC-T therapy uniquely combines cryoablation with four immunotherapy agents injected directly into tumors.
- The Phase 2 LEGION-100 trial is now enrolling US patients under FDA Fast Track designation as of July 2024.
- Dr. Jason Williams, originator of SYNC-T, is not listed in Syncromune’s leadership despite developing the protocol.
- No severe immune-related side effects observed in Phase 1, with some patients showing complete remission of bone metastases.

**Companies:** Syncromune, Inc.
**Countries:** United States, Mexico

[Read the full story on Artvoice](https://artvoice.com/2026/05/02/us-trial-begins-for-prostate-cancer-therapy-developed-by-syncromunes-dr-jason-williamsus-trial-prostate-cancer-therapy-syncromune-williams/)

---

Canonical: https://newsio.io/n/0d3aac69-412a-4a75-96f2-3f53a523a799/a-phase-2-clinical-trial-has-begun-enrolling-patients-in-the-united-states-for-a
Summarized by Newsio from Artvoice. https://newsio.io/how-it-works